Navigation Links
Malvern initiates European user group meetings for chemical imaging

WORCESTERSHIRE , England, 21 June 2007, Malvern Instruments has held the inaugural meeting in Europe for users of the company's near infrared chemical imaging (NIR-CI) systems. The one-day event, which took place on 13 June 2007 was hosted by AstraZeneca in Macclesfield, UK. Malvern customers from some of the world's major pharmaceutical companies joined Malvern's technical and scientific teams for a program that included oral and poster presentations on the application of NIR-CI, and the opportunity to exchange experiences and ideas.

During the first sessions, presentations from users included: 'Chemical imaging and quality by design'; 'Moving NIR chemical imaging from lab to process-based methodology'; 'Applications of NIR imaging in drug development'; and 'Content uniformity determination'. The final parts of the day were devoted to instrumentation and software, together with a session on morphological imaging.

Linda Kidder, Malvern's product manager for chemical imaging systems, felt that the day was extremely valuable. "This was our first chemical imaging user meeting in Europe and we were very pleased with the response from our customers," she said. "Attendees came from a number of different European countries and shared their experiences through oral or poster presentations. The pharmaceutical industry is currently the biggest user of Malvern's chemical imaging systems and it was good to hear more about the various applications for which they are being used." A similar meeting will be held for chemical imaging users in the United States later in the year.

Malvern's recently launched SyNIRgi system underlines the continuing migration of NIR-CI technology from its specialist roots into routine use as a highly desirable, quantitative analytical tool. The hallmarks of SyNIRgi are its rugged construction with no moving parts, modular software that enables the development of turnkey soluti ons, and expandability options for automation accessories. Since NIR chemical imaging provides robust, reliable and automated data collection that is coupled tightly with quantitative, statistical, objective, reproducible and automated data processing tools, it is highly suited for routine analytical measurements. SyNIRgi is designed with this in mind. www.malvern.com <http://www.malvern.com/>

Ends

High resolution image attached or available from Trish Appleton,

Kapler Communications trish@kapleronline.com Ref: MAL/JOB/1229

About Malvern Instruments

Malvern Instruments is a global company that develops, manufactures and markets advanced analytical systems used in characterizing a wide variety of materials, from bulk powders to the latest nanomaterials and delicate macromolecules. Innovative technologies and powerful software produce systems that deliver industrially relevant data enabling customers to make the connection between micro (eg particle size) and macro (bulk) material properties (rheology) and chemical composition (chemical imaging). Malvern laboratory, on-line and in-line solutions are proven in sectors from cement to pharmaceuticals and support the understanding, improvement and optimization of many industrial processes.

Headquartered in Malvern, UK, the company has subsidiary organizations in all major European markets, North America, China, Korea and Japan, key partnerships in India, a global distributor network and a number of applications laboratories around the world. www.malvern.com <http://www.malvern.com/>

For press information, please contact

Trish Appleton, Kapler Communications

Suite 2, Cressner House, 1 2 Huntingdon Street, St Neots, Cambs PE19 1BD UK

Tel: +44 (0) 1480 471117; Fax: +44 (0) 1480 471118 trish@kapleronline.com

USA contact:

Marisa Fraser, Malvern Instruments Inc

10 Southville Road, Southborough, MA 01772, USA

Tel: +1 508 480 0200; Fax: +1 508 460 9692 marisa.fraser@malvern.com

Please send sales enquiries to:

Alison Vines, Malvern Instruments Ltd

Enigma Business Park, Grovewood Road, Malvern, Worcestershire WR14 1XZ UK

Tel: +44 (0) 1684 892456; Fax: +44 (0) 1684 892789 salesinfo@malvern.com


'"/>




Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
7. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. Inspire Announces Presentations at Two European Scientific Conferences
10. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
11. Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... July 11, 2017  Bayer has awarded grants totaling more ... part of its prestigious Bayer Hemophilia Awards Program (BHAP). Four ... Philadelphia and Uniformed Services University of the ... the winners. Grant recipients were announced last night during a ... 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has ... contents of its ginger ale for allegedly containing no ginger. Dr. Pepper produces the ... Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... 21, 2017 , ... West Dermatology is pleased to announce the newest addition ... 2017, Ms. Vu will join West Dermatology’s large network of medical and cosmetic dermatology ... cancer , and more. She graduated from the University of Florida College of Medicine ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... why concussion rates are on the rise, say researchers presenting their work at ... Toronto, Ontario, Canada. , “The combination of evaluating the patterns of change in ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... bone marrow cancer that progresses rapidly without treatment. Newly diagnosed patients face intense ... chance of reoccurrence and relapse. With such a challenging diagnosis that requires ...
Breaking Medicine News(10 mins):